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Abstract
Aims Microvascular dysfunction occurs in Type 2 diabetes and in subjects
with fasting hyperglycaemia. It is unclear whether this dysfunction relates to
dysglycaemia. This study investigated in normogylcaemic individuals whether
a genetic predisposition to diabetes, or indices of insulin resistance including
endothelial markers, were associated with impaired microvascular function.
Methods Maximum microvascular hyperaemia to local heating of the skin
was measured using laser Doppler ¯owmetry in 21 normoglycaemic subjects
with no family history of diabetes (Group 1) and 21 normoglycaemic age, sex
and body mass index-matched offspring of two parents with Type 2 diabetes
(Group 2).
Results Although Group 2 had normal fasting plasma glucose and glucose
tolerance tests, the 120-min glucose values were signi®cantly higher at 6.4
(5.3±6.6) mmol/l (median (25th ± 75th centile)) than the control group at 4.9
(4.6±5.9) mmol/l (P = 0.005) and the insulinogenic index was lower at 97.1
(60.9±130.8) vs. 124.0 (97.2±177.7) (P = 0.027). Skin maximum
microvascular hyperaemia (Group 1: 1.56 (1.39±1.80) vs. Group 2: 1.53
(1.30±1.98) V, P = 0.99) and minimum microvascular resistance which
normalizes the hyperaemia data for blood pressure (Group 1: 52.0 (43.2±67.4)
vs. Group 2: 56.0 (43.7±69.6) mmHg/V, P = 0.70) did not differ in the two
groups. Signi®cant positive associations occurred between minimum
microvascular resistance and indices of the insulin resistance syndrome;
plasminogen activator inhibitor type 1 (Rs = 0.46, P = 0.003), t-PA
(Rs = 0.36, P = 0.03), total cholesterol (Rs = 0.35, P = 0.02), and triglyceride
concentration (Rs = 0.35, P = 0.02), and an inverse association with insulin
sensitivity (Rs = ±0.33, P = 0.03).
Conclusions In normoglycaemic adults cutaneous microvascular vasodilatory
capacity is associated with features of insulin resistance syndrome, particularly
with plasminogen activator inhibitor type 1. A strong family history of Type 2
diabetes alone does not result in impairment in the maximum hyperaemic
response.
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Abbreviations WHO, World Health Organization; vWF, von Willebrand
factor; t-PA, tissue plasminogen activator; PAI-1, plasminogen activator
inhibitor type 1; MMH, maximum microvascular hyperaemia; MMR,
minimal microvascular resistance; Rs, Spearman correlation coef®cient;
HOMA, Homeostasis Model Assessment; AUC, area under the curve; V, volts
Introduction
Although good glycaemic control retards the development
of microvascular complications in Type 2 diabetes (DM),
half the patients have clinical evidence of microangiopathy
at the time of diagnosis [1]. This apparently early
development of diabetic complications could represent
the impact of undiagnosed diabetes; alternatively, it could
result from microvascular impairment associated with the
prediabetic insulin-resistant phase which could predispose
to, or modify the expression of microangiopathy once
hyperglycaemia ensues [2,3]. Evidence for microvascular
functional impairment antedating Type 2 DM comes from
studies of populations with mild elevation of fasting
plasma glucose (5.5±7.8 mmol/l). Such subjects exhibit
limited cutaneous microvascular hyperaemia to a max-
imum thermal stimulus when compared with age- and
sex-matched normoglycaemic controls; furthermore, this
abnormality correlated inversely with calculated insulin
sensitivity [4,5].
The abnormalities in the skin microcirculation which
precede Type 2 DM could still be explicable in terms of
dysglycaemia. To assess whether genetic predisposition to
diabetes might itself be associated with impairment of
microvascular function, we studied normoglycaemic off-
spring all of whom had two parents with Type 2 DM, and
thus an extremely high life-time risk of developing
diabetes [6±8] and compared their responses with a
control population with no family history of the condition.
To determine whether microvascular function could be
related to some feature of the insulin resistance syndrome
in these groups a range of relevant parameters were also
recorded. This included the endothelial markers: von
Willebrand factor (vWF), tissue plasminogen activator
antigen (t-PA), and plasminogen activator inhibitor type 1
(PAI-1). Together with ®brinogen, each of these markers
tends to be increased in obesity and in Type 2 DM, and to
be associated with increased risk of cardiovascular
disease [9].
Patients and methods
Subjects
Subjects of two parents with Type 2 DM were identi®ed by a
national survey. Normal subjects without a ®rst degree family
history of diabetes were recruited from patients' spouses,
friends or hospital staff. Prior to inclusion all subjects under-
went a 75-g oral glucose tolerance test (OGTT) and subjects
with evidence of diabetes according to World Health
Organization (WHO) criteria or a fasting plasma glucose
> 5.5 mmol/l were excluded. Further exclusion criteria com-
prised the presence of hypertension, cardiovascular disease,
body mass index (BMI) > 30 kg/m2, or the consumption of
regular medication. The normal subjects without a family
history of diabetes (Group 1) were then pair matched, for age,
sex (10 F), BMI and, in the case of women, menstrual cycle
status and oral contraceptive pill use, with the 21 normo-
glycaemic family history-positive subjects identi®ed (Group 2).
All subjects gave written informed consent for the study which
was approved by the local medical research ethics committee.
Clinical examination
A full clinical examination and height, weight, BMI (kg/m2),
waist:hip ratio, abdominal skin fold thickness, and arterial
blood pressure (mean of the ®nal three recumbent measure-
ments taken in a series of ®ve recordings at 1-min intervals)
using a Dinamap (Critikon, Tampa, FL, USA) were recorded.
Measurement of maximum microvascular hyperaemia
Maximum microvascular hyperaemia (MMH) was measured,
after a 11-h overnight fast and 30 min acclimatization in a
temperature-controlled laboratory (22 6 1.0°C). Subjects did
not smoke on the study day and had not taken vasoactive
medication for the previous 10 days.
A thermostatically controlled brass heating element set at
43°C was used to heat the skin on the dorsum of the foot for
30 min which achieves maximum microvascular dilation [10].
The erythrocyte ¯ux, a measure of microvascular blood ¯ow,
was then measured using a laser Doppler ¯owmeter (Perimed,
Stockholm, Sweden; model PF3B). The laser Doppler probe is
placed eccentrically through the heating element which can be
rotated in its holder so that eight heated ¯ux measurements can
be made and a mean value calculated. Reproducibility of MMH
was 5.6% (coef®cient of variation (CV)) for subjects measured
on multiple occasions over a 6-month period. The mean arterial
blood pressure was divided by MMH to derive minimal
microvascular resistance (MMR).
Metabolic characterization
At the time of microvascular measurements venous blood was
taken and anticoagulated with trisodium citrate for estimation
of endothelial cell markers. At the clinical screening visit venous
bloods for fasting glucose, insulin, intact proinsulin, total
proinsulin, total cholesterol, and triglycerides were taken.
Insulin sensitivity was calculated from two fasting insulin and
glucose levels using the Homeostasis Model Assessment
(HOMA) model [11,12]. Insulin levels were also taken at 0,
30, 60, 90 and 120 min during the OGTT. The insulinogenic
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index, an indicator of b-cell function, was calculated from the
OGTT data as (insulin 30 min ± insulin 0 min)/(glucose 30 min
± glucose 0 min).
Insulin was measured using an immunoenzymometric assay
(Appligene Oncor/Lifscreen, Uxbridge, UK) calibrated against
IRP 66/304 with no detectable cross-reactivity with intact
proinsulin or 32,33 split proinsulin. Interassay CVs were < 10%
over the range 95±1038 pmol/l. Total proinsulins and intact
proinsulin were also measured by immunometric assays (anti-
bodies 3B1/PEP001 and A6/3B1, respectively) with enzyme
ampli®cation as the detection system (Dako, Ely, UK). Both
assays were calibrated against the First IRR coded 84/611.
Interassay precision CVs were < 10% and < 11% over the
concentration ranges 16±76 pmol/l and 4.7±55 pmol/l, respect-
ively. PAI-1 activity levels were determined by a chromogenic
substrate assay (Coatest PAI; Chomogenix, Epsom, UK; CV
8%); t-PA antigen levels by an ELISA (Biopool, Umea, Sweden;
CV 6%); vWF antigen levels by an ELISA (Dako, Copenhagen,
Denmark; CV 8%); ®brinogen by an automated Claus clotting
assay (Organon, Teknika, Cambridge, UK; CV 5%).
Glucose, cholesterol, triglycerides and HDL-cholesterol
(after precipitation of LDL and VLDL by dextran sulphate)
were measured by Vitros 950 analysers (Johnson & Johnson,
Amersham, UK). The interassay precision CVs for all tests were
< 2%.
Statistical analysis
Data are presented in the text as median and interquartile range
for descriptive purposes. Differences between the groups were
sought using Mann±Whitney U-test. Associations between
variables were sought using Spearman rank correlation coef®-
cients. Multiple regression analysis following transformation of
skewed data was not considered appropriate in view of the
strong correlations between many dependent variables. A
sample size of 20 in each group will provide a 90% power of
detecting a 0.37-V (24% of the normal control level) difference
between the two groups at the 5% level.
Results
Of the 34 subjects screened with two parents with Type 2
DM, three were excluded following OGTT because they
had diabetes and 10 were excluded as they had impaired
glucose tolerance. The remaining 21 offspring and
matched controls had MMH assessed.
Clinical and metabolic characteristics of the two
matched groups are summarized in Table 1. Maximum
microvascular hyperaemia did not differ in the two groups
(Group 1: 1.56 (1.39±1.80) V vs. Group 2: 1.53 (1.30±
1.98) V; P = 0.99), nor did MMR which normalizes the
hyperaemia for blood pressure (Group 1: 52.0 (43.2±67.4)
vs. Group 2: 56.0 (43.7±69.6) mmHg/V, P = 0.70; Fig. 1).
In the total population signi®cant positive associations
were observed between MMR and waist circumference
(Rs = 0.32, P = 0.04), triglyceride (Rs = 0.35, P = 0.02),
total cholesterol (Rs = 0.35, P = 0.02), PAI-1 level
(Rs = 0.46, P = 0.003), t-PA (Rs = 0.36, P = 0.03), and
an inverse association with insulin sensitivity (Rs = ±0.33,
P = 0.03). Minimal microvascular resistance just failed to
reach statistical signi®cance with intact proinsulin
(Rs = 0.30, P = 0.06), total proinsulin (Rs = 0.29,
Variable
Group 1
(control)
Group 2
(family history) P
n (male/female) 21 (11/10) 21 (11/10)
Age (years) 40.0 (33.5±48.5) 42.0 (34.5±49.5) 0.84
BMI (kg/m2) 24.8 (23.2±27.0) 25.4 (24.0±27.4) 0.45
Skin fold thickness (mm) 25.0 (11.6±30.8) 24.3 (17.9±34.8) 0.43
Waist±hip ratio 0.88 (0.78±0.91) 0.85 (0.80±0.89) 0.67
Systolic BP (mmHg) 109 (108±120) 120 (112±124) 0.023
Diastolic BP (mmHg) 72 (62±76) 73 (67±79) 0.19
Fasting plasma glucose (mmol/l) 4.4 (4.2±4.6) 4.5 (4.3±4.7) 0.12
120 min OGTT plasma glucose (mmol/l) 4.9 (4.6±5.9) 6.4 (5.3±6.6) 0.005
Glucose area under curve (mmol/l per h) 12.0 (11.6±12.9) 13.6 (12.6±15.1) 0.001
Fasting insulin (pmol/l) 43.2 (20.4±71.1) 67.9 (22.4±78.9) 0.22
HOMA calculated insulin sensitivity (%) 109.0 (66.2±234.4) 69.3 (59.7±226.3) 0.36
Insulinogenic index (3 109) 124.0 (97.2±177.7) 97.1 (60.9±130.8) 0.027
Total cholesterol (mmol/l) 5.2 (4.2±5.8) 4.5 (4.1±5.0) 0.09
Triglycerides (mmol/l) 0.99 (0.75±1.72) 1.21 (0.73±1.75) 0.58
HDL-cholesterol (mmol/l) 1.24 (1.08±1.48) 1.15 (0.83±1.45) 0.22
PAI-1 (% normal pool) 101.0 (73.7±116.0) 94.0 (76.0±109.0) 0.53
t-PA (ng/ml) 8.1 (4.4±9.5) 7.7 (5.2±10.0) 0.59
vWF (IU/dl) 85.5 (65.3±124.0) 78.0 (70.0±107.0) 0.63
Fibrinogen (g/l) 2.44 (2.16±2.70) 2.41 (2.22±2.93) 0.59
Metabolic characteristics of the two groups of normal subjects: Group 1, normoglycaemic
individuals with no family history of type 2 diabetes; Group 2, normoglycaemic individuals,
both of whose parents had Type 2 diabetes. (Median (interquartile range).) n = 21 unless
stated.
Table 1 Clinical and metabolic characteristics
of the study groups
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P = 0.06) and BMI (Rs = 0.30, P = 0.05). There were no
associations between MMR and age, skinfold thickness,
glucose AUC, insulinogenic index, vWF, ®brinogen.
In Group 1, as well as the strong correlation with PAI-1
(Rs = 0.66, P = 0.001; Fig. 2), MMR was weakly associ-
ated with BMI (Rs = 0.43, P = 0.05), intact proinsulin
(Rs = 0.45, P = 0.04) and t-PA (Rs = 0.44, P = 0.05). In
Group 2, there were only weak positive relationships
between MMR and age (Rs = 0.47, P = 0.03), and
cholesterol (Rs = 0.45, P = 0.04).
Discussion
The study did not demonstrate any signi®cant defect in
cutaneous microvascular vasodilatory capacity in normo-
glycaemic subjects who have two parents with Type 2
DM. These data provide no support for the concept that
an impairment in microvascular function is a genetically
determined intrinsic component of the prediabetic state. It
is conceivable that by excluding subjects with impaired
glucose tolerance on OGTT criteria we may have inad-
vertently studied individuals who had not inherited the
genetic predisposition from their parents. However, this
would not be supported by our observations that the
family history-positive group exhibited subtle evidence of
glucose homeostasis with signi®cantly higher 2-h and
AUC glucose values during their OGTT. The subjects
studied had signi®cantly reduced b-cell function (insulino-
genic index) but the slightly higher fasting insulin levels
and lower calculated insulin sensitivity compared with
controls did not reach statistical signi®cance. Our data in
BMI pair matched individuals agree with a previous study
which showed that obesity matching subjects with and
without a family history of diabetes greatly reduced the
differences in insulin resistance [13]. In previous studies
the microvascular hyperaemic response was related to
insulin sensitivity [5]; since insulin sensitivity was not
signi®cantly reduced in the positive family history group in
the present study, this may have minimized the abnor-
malities of microvascular function.
The study provides further evidence for an association
between features associated with insulin resistance and
microvascular vasodilatory capacity. Previously correl-
ations between fasting insulin, calculated insulin sensitiv-
ity and maximum microvascular hyperaemia in response
to a heating stimulus have been reported in subjects with
fasting hyperglycaemia. SerneÂ et al. recently observed
correlations between insulin sensitivity and microvascular
responsiveness in healthy subjects [14]. This study dem-
onstrates that MMR is inversely correlated with insulin
sensitivity and positively with features of insulin resistance
syndrome, particularly PAI-1. Subjects with insulin resist-
ance tend to have higher PAI-1 and t-PA antigen levels [15]
which, in the present study, is clearly associated with
impaired microvascular vasodilatory capacity, particu-
larly in the subjects without a family history of diabetes.
Whether PAI-1 is causally linked or whether it is simply a
marker of the insulin-resistant state and it is this or some
common antecedent which is the key determinant remains
unclear.
Two recent studies on vascular reactivity in relatives of
Type 2 DM have yielded con¯icting data. Caballero et al.
demonstrated impaired vasodilation in both the macro-
and microcirculation in individuals with a family history
of Type 2 DM in one or both parents. However, those
individuals with a positive family history of diabetes had
signi®cantly higher systolic and diastolic blood pressures
compared with controls, perhaps suggesting an increased
familial risk for hypertension which itself is known to be
associated with defective vascular function and may
Figure 1 Minimum microvascular resistance in normoglycaemic
individuals with no family history of diabetes (control) and
normoglycaemic individuals with two parents with Type 2 diabetes
(family history).
Figure 2 The relationship between minimum microvascular resistance
and plasminogen activator inhibitor activity in a group of
normoglycaemic individuals with no family history of diabetes.
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contribute to the ®ndings of this paper [16]. In contrast,
Balletshofer et al., who examined the ¯ow-related brachial
artery dilation in a similar population, showed normal
endothelium-dependent vasodilation in the group as a
whole. Subtle vasodilatory impairment was noted in an
insulin-resistant subgroup of the offspring [17]. In con-
trast to the two studies above, all of the offspring
examined in the present study had two parents with
Type 2 DM, a cohort which is at a much higher risk of
developing the same condition [6±8]. Subjects studied had
minimal evidence of insulin resistance compared with
their age-matched control group. The subjects were
relatively young and were therefore less likely to have
clinical vascular disease or aged-related vascular dysfunc-
tion. The vascular tests utilized in the present study
assessed the overall integrity of the microvascular response
rather than examining the speci®c endothelial-dependent
vasodilatory mechanisms. Our data are in agreement with
those of Balletshofer et al. and suggest that overall
vascular function is not abnormal in the offspring of
parents with Type 2 DM, although abnormalities may be
described when insulin resistance is also apparent in the
subjects. The differences between our studies and that of
Callabero et al. are likely to re¯ect differences in the study
cohort characterization such as ethnic status, as well as
methodology.
The maximum microvascular hyperaemic response to
local heating is likely to involve neurogenic and endothe-
lial-dependent mechanisms compounded by vessel wall
structural changes. It is known to be impaired in
normotensive offspring with a strong family history of
hypertension [18]. Given the link between predisposition
to Type 2 DM and blood pressure, exempli®ed again in
this study, perhaps microvascular developmental changes
as a result of insulin resistance in fetal or early neonatal life
lead to increased peripheral vascular resistance and the
vasodilatory impairment observed [19].
In conclusion, in normoglycaemic adults cutaneous
microvascular vasodilatory capacity is associated with
features of the insulin resistance syndrome, particularly
PAI-1. However, a strong family history of Type 2 DM
alone does not appear to result in impairment of
microvascular vasodilatory capacity.
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